Astria Total Stockholder Equity vs Common Stock Analysis

ATXS Stock

USD 9.54 0.11 1.17%

Astria Therapeutics financial indicator trend analysis is way more than just evaluating Astria Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Astria Therapeutics is a good investment. Please check the relationship between Astria Therapeutics Total Stockholder Equity and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.

Total Stockholder Equity vs Common Stock

Total Stockholder Equity vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Astria Therapeutics Total Stockholder Equity account and Common Stock. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Astria Therapeutics' Total Stockholder Equity and Common Stock is 0.91. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Common Stock in the same time period over historical financial statements of Astria Therapeutics, assuming nothing else is changed. The correlation between historical values of Astria Therapeutics' Total Stockholder Equity and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Astria Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Stockholder Equity i.e., Astria Therapeutics' Total Stockholder Equity and Common Stock go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock

Most indicators from Astria Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Astria Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.Selling General Administrative is likely to drop to about 12.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 82.6 M in 2024

Astria Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Short Term Debt	Common Stock	Short Term Investments	Other Liab	Net Tangible Assets	Current Deferred Revenue	Other Assets
Total Assets		0.6	0.26	0.95	0.09	-0.81	-0.93	0.32	0.81	0.85	0.94	1.0	0.96	-0.45	0.78	0.95	-0.41	1.0	-0.61	-0.28	0.83	0.72	-0.65	0.96	-0.76	0.38
Other Current Liab	0.6		0.69	0.56	-0.03	-0.89	-0.54	0.57	0.89	0.45	0.55	0.59	0.77	-0.29	0.79	0.63	-0.2	0.6	-0.33	-0.19	0.61	-0.07	-0.41	0.61	-0.86	-0.45
Total Current Liabilities	0.26	0.69		0.38	0.0	-0.57	-0.33	0.7	0.57	0.17	0.19	0.26	0.39	-0.55	0.59	0.4	-0.49	0.27	-0.06	0.42	0.57	-0.25	-0.21	0.25	-0.4	-0.49
Total Stockholder Equity	0.95	0.56	0.38		0.2	-0.74	-0.97	0.49	0.74	0.83	0.86	0.95	0.9	-0.7	0.83	0.99	-0.66	0.95	-0.65	-0.08	0.91	0.68	-0.75	0.92	-0.69	0.38
Property Plant And Equipment Net	0.09	-0.03	0.0	0.2		0.13	-0.2	0.16	-0.12	0.49	0.13	0.08	0.06	-0.36	0.36	0.2	-0.37	0.08	-0.23	0.07	0.19	0.21	-0.41	0.18	-0.01	0.28
Net Debt	-0.81	-0.89	-0.57	-0.74	0.13		0.72	-0.42	-1.0	-0.54	-0.69	-0.8	-0.9	0.31	-0.79	-0.78	0.23	-0.81	0.43	0.27	-0.71	-0.19	0.45	-0.74	0.87	0.23
Retained Earnings	-0.93	-0.54	-0.33	-0.97	-0.2	0.72		-0.51	-0.72	-0.8	-0.82	-0.93	-0.89	0.65	-0.83	-0.98	0.63	-0.93	0.8	0.24	-0.85	-0.66	0.83	-0.89	0.65	-0.35
Accounts Payable	0.32	0.57	0.7	0.49	0.16	-0.42	-0.51		0.42	0.21	0.17	0.32	0.36	-0.72	0.59	0.52	-0.69	0.32	-0.33	0.23	0.48	-0.03	-0.61	0.29	-0.3	-0.24
Cash	0.81	0.89	0.57	0.74	-0.12	-1.0	-0.72	0.42		0.55	0.7	0.8	0.9	-0.32	0.8	0.78	-0.24	0.81	-0.41	-0.23	0.72	0.18	-0.43	0.74	-0.89	-0.23
Non Current Assets Total	0.85	0.45	0.17	0.83	0.49	-0.54	-0.8	0.21	0.55		0.93	0.85	0.82	-0.42	0.77	0.83	-0.39	0.85	-0.57	-0.24	0.77	0.74	-0.65	0.92	-0.64	0.52
Non Currrent Assets Other	0.94	0.55	0.19	0.86	0.13	-0.69	-0.82	0.17	0.7	0.93		0.93	0.92	-0.32	0.74	0.86	-0.28	0.93	-0.56	-0.31	0.8	0.74	-0.56	0.97	-0.76	0.45
Cash And Short Term Investments	1.0	0.59	0.26	0.95	0.08	-0.8	-0.93	0.32	0.8	0.85	0.93		0.95	-0.45	0.77	0.94	-0.4	1.0	-0.6	-0.28	0.83	0.72	-0.65	0.95	-0.75	0.39
Common Stock Shares Outstanding	0.96	0.77	0.39	0.9	0.06	-0.9	-0.89	0.36	0.9	0.82	0.92	0.95		-0.41	0.87	0.94	-0.35	0.96	-0.65	-0.33	0.85	0.53	-0.63	0.95	-0.88	0.15
Non Current Liabilities Total	-0.45	-0.29	-0.55	-0.7	-0.36	0.31	0.65	-0.72	-0.32	-0.42	-0.32	-0.45	-0.41		-0.66	-0.67	0.99	-0.45	0.46	-0.46	-0.73	-0.27	0.67	-0.45	0.28	-0.16
Other Current Assets	0.78	0.79	0.59	0.83	0.36	-0.79	-0.83	0.59	0.8	0.77	0.74	0.77	0.87	-0.66		0.89	-0.59	0.77	-0.65	-0.1	0.85	0.29	-0.74	0.82	-0.82	-0.04
Other Stockholder Equity	0.95	0.63	0.4	0.99	0.2	-0.78	-0.98	0.52	0.78	0.83	0.86	0.94	0.94	-0.67	0.89		-0.64	0.95	-0.74	-0.17	0.91	0.62	-0.79	0.93	-0.74	0.29
Total Liab	-0.41	-0.2	-0.49	-0.66	-0.37	0.23	0.63	-0.69	-0.24	-0.39	-0.28	-0.4	-0.35	0.99	-0.59	-0.64		-0.41	0.46	-0.47	-0.68	-0.29	0.67	-0.4	0.19	-0.21
Total Current Assets	1.0	0.6	0.27	0.95	0.08	-0.81	-0.93	0.32	0.81	0.85	0.93	1.0	0.96	-0.45	0.77	0.95	-0.41		-0.61	-0.28	0.83	0.72	-0.65	0.95	-0.76	0.38
Short Long Term Debt Total	-0.61	-0.33	-0.06	-0.65	-0.23	0.43	0.8	-0.33	-0.41	-0.57	-0.56	-0.6	-0.65	0.46	-0.65	-0.74	0.46	-0.61		0.5	-0.57	-0.45	0.83	-0.67	0.44	-0.24
Short Term Debt	-0.28	-0.19	0.42	-0.08	0.07	0.27	0.24	0.23	-0.23	-0.24	-0.31	-0.28	-0.33	-0.46	-0.1	-0.17	-0.47	-0.28	0.5		0.12	-0.24	0.31	-0.32	0.25	-0.09
Common Stock	0.83	0.61	0.57	0.91	0.19	-0.71	-0.85	0.48	0.72	0.77	0.8	0.83	0.85	-0.73	0.85	0.91	-0.68	0.83	-0.57	0.12		0.48	-0.58	0.85	-0.73	0.2
Short Term Investments	0.72	-0.07	-0.25	0.68	0.21	-0.19	-0.66	-0.03	0.18	0.74	0.74	0.72	0.53	-0.27	0.29	0.62	-0.29	0.72	-0.45	-0.24	0.48		-0.51	0.7	-0.18	0.91
Other Liab	-0.65	-0.41	-0.21	-0.75	-0.41	0.45	0.83	-0.61	-0.43	-0.65	-0.56	-0.65	-0.63	0.67	-0.74	-0.79	0.67	-0.65	0.83	0.31	-0.58	-0.51		-0.7	0.39	-0.3
Net Tangible Assets	0.96	0.61	0.25	0.92	0.18	-0.74	-0.89	0.29	0.74	0.92	0.97	0.95	0.95	-0.45	0.82	0.93	-0.4	0.95	-0.67	-0.32	0.85	0.7	-0.7		-0.78	0.39
Current Deferred Revenue	-0.76	-0.86	-0.4	-0.69	-0.01	0.87	0.65	-0.3	-0.89	-0.64	-0.76	-0.75	-0.88	0.28	-0.82	-0.74	0.19	-0.76	0.44	0.25	-0.73	-0.18	0.39	-0.78		0.16
Other Assets	0.38	-0.45	-0.49	0.38	0.28	0.23	-0.35	-0.24	-0.23	0.52	0.45	0.39	0.15	-0.16	-0.04	0.29	-0.21	0.38	-0.24	-0.09	0.2	0.91	-0.3	0.39	0.16

Click cells to compare fundamentals

Astria Therapeutics Account Relationship Matchups

Astria Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	41.8M	47.5M	127.5M	230.6M	254.7M	267.4M
Other Current Liab	2.6M	4.2M	3.3M	(788K)	9.7M	10.2M
Total Current Liabilities	5.0M	6.4M	5.2M	582K	11.6M	6.2M
Total Stockholder Equity	35.7M	40.7M	122.3M	221.2M	243.1M	255.3M
Property Plant And Equipment Net	2.3M	966K	394K	948K	363K	706.5K
Net Debt	(7.6M)	(23.9M)	(86.1M)	(19.6M)	(175.4M)	(166.6M)
Retained Earnings	(223.6M)	(260.9M)	(455.8M)	(507.6M)	(580.5M)	(551.5M)
Accounts Payable	1.2M	1.5M	1.6M	788K	1.5M	1.3M
Cash	9.9M	24.9M	86.5M	20.5M	175.7M	184.5M
Non Current Assets Total	2.8M	1.1M	439K	4.2M	3.7M	3.9M
Non Currrent Assets Other	473K	165K	45K	3.2M	3.4M	3.5M
Cash And Short Term Investments	36.2M	44.9M	125.5M	226.4M	246.7M	259.0M
Common Stock Shares Outstanding	1.9M	3.1M	8.9M	14.6M	30.1M	31.6M
Liabilities And Stockholders Equity	41.8M	47.5M	127.5M	230.6M	254.7M	267.4M
Non Current Liabilities Total	56K	1.0M	397K	1.9M	8.8M	0.0
Other Current Assets	2.7M	1.4M	1.6M	1.3M	4.2M	4.5M
Other Stockholder Equity	259.3M	301.5M	481.7M	632.5M	823.6M	864.8M
Total Liab	6.1M	6.8M	5.2M	9.4M	11.6M	17.9M
Total Current Assets	39.0M	46.3M	127.1M	226.4M	250.9M	263.5M
Common Stock	12K	20K	13K	28K	41K	43.1K
Short Term Investments	26.3M	20M	39M	205.9M	71M	54.9M
Net Tangible Assets	35.7M	40.7M	25.9M	124.8M	143.5M	150.7M
Other Assets	473K	165K	45K	3.2M	1.0	0.95
Common Stock Total Equity	7K	12K	20K	28K	32.2K	20.0K
Net Invested Capital	35.7M	40.7M	25.9M	124.8M	147.8M	155.2M
Property Plant And Equipment Gross	2.3M	966K	394K	948K	363K	616.8K
Net Working Capital	33.9M	39.9M	121.9M	218.6M	239.4M	251.4M
Capital Stock	12K	20K	96.4M	96.4M	95.4M	52.8M

Pair Trading with Astria Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astria Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Astria Stock

0.89	VRDN	Viridian Therapeutics	Pair Corr
0.89	EFTR	Effector Therapeutics	Pair Corr

Moving against Astria Stock

0.74	DSGN	Design Therapeutics	Pair Corr
0.71	ELYM	Eliem Therapeutics	Pair Corr
0.63	ELVN	Enliven Therapeutics	Pair Corr
0.63	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr

The ability to find closely correlated positions to Astria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astria Therapeutics to buy it.

The correlation of Astria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Astria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Astria Therapeutics is a strong investment it is important to analyze Astria Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Astria Therapeutics' future performance. For an informed investment choice regarding Astria Stock, refer to the following important reports:

How To Invest In Astria

Details

Is Astria Stock a good investment?

Details

What is Astria Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astria Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Astria Stock analysis

When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Fundamental Analysis View fundamental data based on most recent published financial statements
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Global Correlations Find global opportunities by holding instruments from different markets
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Astria Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astria Therapeutics. If investors know Astria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.40)

Return On Assets

(0.16)

Return On Equity

(0.28)

The market value of Astria Therapeutics is measured differently than its book value, which is the value of Astria that is recorded on the company's balance sheet. Investors also form their own opinion of Astria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astria Therapeutics' market value can be influenced by many factors that don't directly affect Astria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Astria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Astria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Astria Total Stockholder Equity vs Common Stock Analysis

Total Stockholder Equity vs Common Stock

Total Stockholder Equity vs Common Stock Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Common Stock

Astria Therapeutics fundamental ratios Correlations

Astria Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Astria Therapeutics fundamental ratios Accounts

Pair Trading with Astria Therapeutics

Moving together with Astria Stock

Moving against Astria Stock

Complementary Tools for Astria Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Total Liab	+ 0.99	Non Current Liabilities Total
Net Tangible Assets	+ 0.97	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.97	Total Stockholder Equity
Total Current Assets	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Total Assets